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Abstract
Background: Hepatocellular carcinoma (HCC) is the most commonly occurring primary liver cancer and ranks as the fifth
most frequently occurring cancer, overall, and the third leading cause of cancer deaths, worldwide. At present, effective
therapeutic options available for HCC are limited; consequently, the prognosis for these patients is poor. Our aim in the
present study was to identify a novel target for antibody therapy against HCC.
Methodology/Principal Findings: We used Western blot and flow cytometric and immunocytochemical analyses to
investigate the regulation of FGFR1 expression by interferon-a/b in several human hepatic cancer cell lines. In addition, we
tested the efficacy of combined treatment with anti-FGFR1 monoclonal antibody and interferon-a/b in a murine xenograft
model of human HCC. We found that interferon-a/b induces expression of FGFR1 in human HCC cell lines, and that an anti-
FGFR1 monoclonal antibody (mAb) targeting of the induced FGFR1 can effectively inhibit growth and survival of HCC cells
in vitro and in vivo. Moreover, the combination of interferon-a, anti-FGFR1 mAb and peripheral blood mononuclear cells
(PBMCs) exerted a significant antitumor effect in vitro.
Conclusions: Our results suggest that the combined use of an anti-FGFR1 antibody and interferon-a/b is a promising
approach to the treatment of HCC.
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Introduction
Hepatocellular carcinoma (HCC) is the most commonly
occurring primary liver cancer and ranks as the fifth most
frequently occurring cancer, overall, and the third leading cause
of cancer deaths, worldwide [1]. At present, surgery, percutane-
ous therapies such as ethanol injection and radiofrequency
ablation, and transcatheter therapies such as arterial chemoem-
bolization are employed in the treatment of HCC. These
approaches can selectively remove and kill cancer cells, which
makes them useful for control of the local tumor; however, they
are not sufficient to improve the prognosis of HCC patients, as
the disease readily recurs due to blood-born metastases (e.g.,
intrahepatic metastasis and vascular infiltration) or the develop-
ment of new HCCs (multicentric carcinogenesis). Consequently,
the 1-year and 3-year survival rates for HCC are only 36% and
17%, respectively [2]. The weaknesses of the current HCC
treatments include incomplete inhibition of multicentric carcino-
genesis, difficulties in controlling intraportal infiltration, and the
inability to prevent deterioration of hepatic functional reserve or
foster its restoration. Thus development of new treatments that
improve the prognosis of HCC patients and which can also be
used in elderly and advanced stage patients would be highly
desirable.
Targeting cell surface molecules using mAbs is an emerging
strategy in cancer therapy, and mAbs against cancer-related
surface molecules such as EGFR, HER2 and CD20 have been
successfully employed [3,4,5]. However, cell surface expression of
antigenic molecules is often weak and heterogeneous, which
prevents the efficient targeting of tumors [6] and, to date, only a
few pilot studies examining expression of HCC-associated antigens
have been carried out [7].
PLoS ONE | www.plosone.org 1 May 2011 | Volume 6 | Issue 5 | e19618Interferons (IFNs), which are widely used for the treatment of
neoplasias and viral diseases, enhance expression of several cell
surface molecules both in vitro and in xenograft tumor models
[8,9]. Induction of gene expression by IFN is a complex
phenomenon that involves activation of target genes via
phosphorylation of STATs by JAK kinase [10]. In addition, IFNs
can induce expression of interferon regulatory factors (IRFs) and
transcription factors, which then induce genes involved in
apoptosis and immune responses [11]. IFNs are already being
used to treat most hepatitis patients, and their effects suggest
targeting cell surface molecules induced by IFN may be a useful
strategy for treating HCC. Our aim in the present study was to use
HCC cell lines and a murine xenograft model of human HCC to
examine the changes in gene expression induced by IFN and to
identify potential targets for antibody therapy. Our findings
suggest IFN-a/b-induced fibroblast growth factor receptor 1
(FGFR1) could be a novel therapeutic target for the treatment of
HCC.
Results
Induction of FGFR1 expression by IFN-a/b in HCC
xenografts
To identify genes up-regulated by IFN in HCC cells, we
performed a microarray analysis using cDNA prepared from
tumors grown in SCID mice subcutaneously administrated
HepG2 cells, a human hepatic cancer cell line. The results of
the microarray analysis are summarized in Figure 1A. Among the
genes up-regulated by IFN was FGFR1, which encodes a receptor
tyrosine kinase. Real-time PCR analysis confirmed induction of
FGFR1 transcription by both IFN-a and IFN-b (Figure S1), and
corresponding increases in FGFR1 protein were observed in
HepG2, Huh-7 and CHC4 cells (Figure 1B–D). We then used
immunohistochemical staining to examine the distribution of IFN-
a/b-induced FGFR1 within the tumors and found that levels of
FGFR1 were increased at the cell membrane and in the cytoplasm
of HCC cells (Figure 1E).
Development of an anti-FGFR1 monoclonal antibody
We developed novel anti-FGFR1 mAbs by immunizing BALB/
c mice with an FGFR1 expression vector. Six antibodies
recognizing FGFR1 were isolated from the mice, two of which,
designated A2C9-1 and A2D11-1, showed strong affinity in
ELISAs and were characterized further. For kinetic analyses, the
extracellular domain of FGFR1 was covalently coupled to a CM-5
sensor chip at low density (215 response units of FGFR1), after
which we determined the Kd values for A2C9-1 and A2D11-1 to
be 209 nM and 7.03 mM, respectively (Figure S2A). Thus A2C9-1
showed the strongest affinity for FGFR1. Flow cytometric analysis
confirmed that A2C9-1 reacts with FGFR1 (Figure 2), and
Western blot analysis showed the molecular weight of the
ectopically expressed FGFR1 to be around 115 kDa (Figure S2B).
Anti-FGFR1 mAbs inhibit HCC cell growth in vitro
We next examined the effects of A2C9-1 and A2D11-1 mAbs
on the growth of hepatic cancer cells (Figure 3). IFN-a showed
some antitumor activity against hepatic cancer cells, and weak
growth suppression was seen when A2C9-1 or A2D11-1 was
added to cultures in the absence of IFN-a. On the other hand,
treatment with a combination of A2C9-1 and IFN-a significantly
reduced cell survival, as compared to treatment with IFN-a alone
(P=0.01) (Figure 3). The effect of A2D11-1 in combination with
IFN-a was no greater than the effect of IFN-a alone.
Effects of A2C9-1 with and without IFN-a in a mouse
xenograft tumor model
We next tested the antitumor effects of an anti-FGFR1 mAb in
a mouse xenograft model of human HCC (Figure 4A and B). In
mice treated with only A2C9-1 or IFN-a, tumor volumes did not
differ from the control group administered PBS. However,
treatment with IFN-a+A2C9-1 had an inhibitory effect on tumor
growth, though the suppression was not statistically significant.
Finally, in mice treated with IFN-a+A2C9-1+PBMCs (peripheral
blood mononuclear cells), there was a significant antitumor effect,
as compared to groups treated with PBS (p=0.026), INF-a
(p=0.03), A2C9-1 (p=0.014), PBMC (p=0.022) or IFN-
a+PBMCs (p=0.007). In fact, the tumor disappeared in 2 of the
4 animals tested. During the course of the experiments we detected
no cytotoxicity against normal hepatocytes (data not shown).
Histological analysis revealed marked infiltration by mononuclear
cells of the residual tumor tissues from mice treated with IFN-
a+A2C9-1+PBMCs, but no such infiltration was observed in
tumor tissues from mice in the other groups (Figure S3).
IFN enhances accumulation of anti-FGFR1 mAb within
tumors
To further confirm that the observed regression of the
xenografts was related to the treatment with A2C9-1 mAb, Alexa
Fluor 680-conjugated A2C9-1 was injected into the tail veins of
tumor-bearing SCID mice, after which the targeting of the tumor
by A2C9-1 was evaluated in the same animals at different time
points using an optical molecular imaging system (Figure 5A and
B). In mice pretreated with IFN-a, A2C9-1 selectively and time-
dependently accumulated within the tumors during the period
from 24 h to 192 h after its administration. By contrast, only
negligible levels of mAb were detected in control mice adminis-
tered A2C9-1+PBS. We also confirmed that there was no
accumulation of an Alexa Fluor 680-conjugated control antibody
(data not shown). It thus appears that IFN-a enhances the
accumulation of anti-FGFR1 mAb in vivo, most likely by up-
regulating FGFR1.
Discussion
In this study, we found that FGFR1 can serve as a novel target
for antibody therapy in HCC. More specifically, combined
treatment with IFN-a/b and an anti-FGFR1 mAb (A2C9-1)
showed strong growth suppressive effects on human HCC cells in
vitro and in vivo. Five isoforms of the transmembrane receptor
FGFR (FGFR1–4 and FGFR5/1L) are known to be expressed in
mammals [12]. Each consists of three extracellular immunoglob-
ulin-like domains, a transmembrane domain, and two intracellular
tyrosine kinase domains. FGF binds to the FGFR via two of the
immunoglobulin-like domains (II and III). During FGFR expres-
sion, alternative splicing of FGFR transcripts produces multiple
splice variants with different tissue-specific ligand specificities [13].
Among them, FGFR1 has been shown to be expressed in HCC
and is known to promote the development of HCC in response to
carcinogenic stimulation [14]. FGFR1 is not expressed in
noncancerous hepatocytes. FGFR1-mediated signaling is involved
in cancer cell growth and infiltration, as well as in angiogenesis
[15], which is already a target for antitumor therapies [16]. In
addition, previous studies have shown elevated expression of
FGFR ligands, including FGF1 and FGF2, in primary HCC
tissues and hepatic cancer cell lines [17,18,19,20], strongly
suggesting FGF signaling plays a key role in the development of
HCC. These characteristics make FGFR1 an attractive molecular
target for treating HCC.
Anti-FGFR1 Antibody and IFN-a/b Treatment for HCC
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weak and heterogeneous expression of cell surface antigens. To
overcome this problem, we examined genes up-regulated by IFN
in HCC xenografts. We found that expression of FGFR1 is
induced by IFN-a/b and that treating HCC cells with a
combination of IFN-a/b and an anti-FGFR1 mAb effectively
inhibits the growth and survival of HCC cells. Thus, one reason
for the insufficient therapeutic effect of anticancer drugs targeting
FGFR1 appears to be is that, without induction, expression of
FGFR1 on cancer cells is not sufficient for effective treatment.
Consistent with this idea, our immunohistochemical analysis
showed expression of FGFR1 to be very low in untreated HCC
cells. Notably, epidermal growth factor receptor (EGFR) is also
up-regulated by IFN [21], and this up-regulation of EGFR is a
crucial factor underlying the susceptibility of affected cancer cells
to anti-EGFR antibody therapy [22]. Taken together, these
findings suggest treatment with a combination of IFN and an
antibody may be an effective therapeutic strategy against various
types of cancer.
The molecular mechanism by which IFN-a/b induces FGFR1
expression remains unknown. It is known, however, that the
antitumor and antiviral effects of IFN involve changes in the
transcriptional regulation of various genes [23], and that IFN-
inducible genes contain an interferon response element (ISRE) in
Figure 1. Induction of FGFR1 by IFN-a/b treatment in hepatic cancer cells. A, Summary of genes induced by IFN-a in hepatic cancer cell lines
and HepG2-xenografts. Expression of genes induced by IFN-a was examined using DNA array analysis, and expression of FGFR1 was found to be
strongly induced. B, Western blot showing IFN-a/b-induced expression of FGFR1 in human hepatic cancer cells. Relative protein levels are indicated
below. C, Flow cytometric analysis showing IFN-a/b-induced expression of FGFR1 in human hepatic cancer cells: black, no antibody; green, no IFN;
Pink, IFN-a; Blue, IFN-b. D, Western blot showing the time course of FGFR1 expression after treatment with IFN-a/b. The immunoblots were done
using total lysates from HepG2-xenografts. E, IFN-a/b-induced FGFR1 expression in excised tissues from HepG2-xenografts. FGFR1 was stained using
anti-FGFR1 antibody.
doi:10.1371/journal.pone.0019618.g001
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program, we identified several putative ISREs in the 59 UTR of
FGFR1, suggesting that FGFR1 could be a direct target of type I
IFN (data not shown). Further study will be necessary to determine
precisely how interferon induces FGFR1.
We also do not yet fully understand the molecular mechanism
by which our antibody exerted its anti-tumor effect, though there
are several possibilities. Many of the tumor-expressed targets of
therapeutic antibodies are growth factor receptors. For example,
anti-EGFR antibodies, including Cetuximab, have been shown to
block growth factor signaling by preventing the ligand from
binding to its receptor, or by preventing receptor dimerization
[25]. It is highly likely that A2C9-1 suppresses tumor cell growth
through a similar mechanism by targeting IFN-induced FGFR1. It
was also reported that the binding of an antibody to a growth
factor receptor results in the internalization of the antibody-
receptor complex, and the down-regulation of downstream
signaling [26]; however, we observed no A2C9-1-induced
internalization in cancer cells (data not shown). Thirdly, antibodies
against growth factor receptors also exert growth suppressing
effects via the immune system [27]. Here, for example, we showed
that IFN-a/b enhances the surface expression of FGFR1, perhaps
enabling an anticancer effect based on antibody-dependent cell-
mediated cytotoxicity to accompany the binding of anti-FGFR1
mAb to the receptor. The results of our in vivo experiment showing
the importance of PBMCs to the antitumor effects of A2C9-1 is
consistent with the idea that this antibody strongly stimulates
antibody-dependent cell-mediated cytotoxicity.
In summary, we found that IFN-a/b induces expression of
FGFR1 and that treatment with a combination of IFN-a/b and an
anti-FGFR1 mAb suppresses HCC cell growth in vitro and in vivo.
We also confirmed that IFN-a/b enhances the accumulation of
the anti-FGFR1 mAb within tumors. This treatment protocol
selectively inhibits the growth of HCC cells without affecting
normal cells, which suggests it could be used in the treatment of
HCC without reducing hepatic preliminary performance. We
therefore suggest that our results may provide the basis for a novel
approach to the treatment of HCC, for which there is no effective
therapy at the moment.
Materials and Methods
Cell lines and experimental animals
Human hepatic cancer cell lines (HepG2, Huh-7 and CHC4) were
obtained from the Japanese Collection of Research Bioresources
(Tokyo,Japan)andcultured as recommended.Cellsweremaintained
in Dulbecco’s modified Eagle’s medium supplemented with 10% fetal
bovine serum and penicillin/streptomycin at 37uCu n d e ra n
atmosphere of humidified air with 5% CO2.P e r i p h e r a lb l o o d
mononuclear cells (PBMCs) were isolated from healthy volunteers
using Ficoll-Paque (GE Healthcare Life Science, Uppsala, Sweden)
and used as effector cells in SCID mice. All donors provided written
informed consent before collection in accordance with the Declara-
tion of Helsinki, and all protocols using human samples were
approved by the institutional review board of Sapporo Medical
University. Whole PBMCs (1610
7)s u s p e n d e di n0 . 2m lo fR P M I
1640 were intraperitoneally injected into each SCID mouse. All
animal experiments were conducted in accordance with accepted
standards of animal care and approved by the Institutional Animal
Care and Use Committee of Sapporo Medical University.
Figure 2. Development of anti-FGFR1 mAbs. Flow cytometric analysis showing the expression level of FGFR1 and specificity of A2C9-1 mAb.
Left: the graphs show the results obtained with lysates from NIH3T3 cells into which M19B2 cDNA introduced (control). Right: the graphs show the
results with lysates from NIH3T3 cells into which full-length FGFR1 cDNA was introduced.
doi:10.1371/journal.pone.0019618.g002
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For microarray analysis, HepG2 cells (1610
6 cells) were initially
xenografted into severe combined immunodeficient (SCID) mice.
Three weeks later, when the resultant tumor had reached 6–7 mm
in diameter, IFN-a (OIFH; Otsuka Pharmaceutical Co., Ltd.,
Tokushima, Japan) was subcutaneously injected at a dose of
2000 U/mouse. Samples of tumor tissue were collected before and
24 h after injection of the IFN-a. RNA was extracted from the
collected tissues using Trizol (Invitrogen, Carlsbad, CA, USA) and
reverse transcribed to cDNA using Superscript III (Invitrogen).
The cDNA was then reacted using Gene Navigator cDNA Array
Filter-human cancer (Toyobo, Osaka, Japan) and subjected to
DNA array analysis using a Fluor-S Multi Imager (Bio-Rad
Laboratories, Hercules, CA, USA).
Real-time RT-PCR analysis
HepG2 (1610
6 cells) cells were subcutaneously xenografted into
the backs of SCID mice. When the inoculated tumor reached
10 mm in diameter, IFN-a (OIFH) or IFN-b (FeronH; manufac-
tured by Toray Industries, Inc., Tokyo, Japan) was administered
intravenously at a dose of 2000 U/mouse, and samples of tumor
tissue were collected 0, 1, 3, 8, 24 and 48 h after administration.
Total RNA was purified from the samples using a RNeasy Kit
(QIAGEN, Hilden, Germany), and single-strand cDNA was
synthesized from 1 mg of total RNA using a First-Strand cDNA
Synthesis Kit (GE Healthcare Life Science, Uppsala, Sweden).
Real-time quantitative analysis was performed using SYBR Green
I (Roche, Basel, Switzerland) with a LightCycler Real-time PCR
system (Roche). Levels of FGFR1 and OAS1 (control) mRNA
expression were normalized to the expression of GAPDH mRNA.
Primer sets for FGFR1 (sense, 59-GGA CGA TGT GCA GAG
CAT CAA CTG-39; anti-sense, 59-AAC TTC ACT GTC TTG
GCA GCC GG-39), OAS1 (sense, 59-CAT CCG CCT AGT CAA
GCA CTG-39; anti-sense, 59-CCA CCA CCC AAG TTT CCT
GTA-39) and GAPDH (sense, 59-GAA GGT GAA GGT CGG
AGT C-39; anti-sense, 59-GAA GAT GGT GAT GGG ATT-TC-
39) were synthesized at Greiner Bio-One (Tokyo, Japan).
Western blot analysis
HepG2, Huh-7 or CHC4 cells were incubated for 48 h in the
presence of IFN-a or IFN-b (1,000 IU/ml), after which the cells were
lysed in sample buffer (50 mM Tris-HC1, pH 6.8, 6% 2-mercapto-
ethanol, 2% SDS, 0.004% bromophenol blue, and 10% glycerol).
Proteins in samples of lysate were separated by 7.5% polyacrylamide
gel electrophoresis and then transferred onto a nitrocellulose
membrane (Bio-Rad Laboratories). After blocking the membrane
with 2% bovine serum albumin (BSA) in PBS for 1 h at room
temperature, it was incubated with anti-human FGFR1 antibody (sc-
121, Santa Cruz Biotechnology, Santa Cruz, CA, USA) for 1 h at
room temperature. The blot was then developed with 0.005% H202-
3, 39-diaminobenzidine using an immunoperoxidase ABC kit
(Vectastain ABC kit, Vector Labs, Burlingame, CA, USA).
Figure 3. Antitumor activity of anti-FGFR1 mAbs in combination with IFN-a in vitro. In the graph, the survival rate among cultured HepG2
HCC cells is shown on the vertical axis, and the incubation time after administration of the indicated drugs is shown on the horizontal axis. PBS is the
negative control. Symbols and bars represent means 6 SD. Note that treatment with a combination of A2C9-1 and IFN-a significantly reduced cell
survival, as compared to treatment with IFN-a alone (P=0.01).
doi:10.1371/journal.pone.0019618.g003
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Forty-eight hours after administration of IFN-a, expression of
FGFR1 was assessed using flow cytometry. Cells in suspension
(4610
5 cells/tube) were washed with 2 mL of washing buffer
(0.2% bovine serum albumin, 0.1% NaN3/10 mmol/L phos-
phate-buffered saline, pH 7.4) and centrifuged at 300 g for 5 min
at 4uC, after which the supernatant was removed. The remaining
cell pellet was fixed in 0.25% paraformaldehyde for at least 15 min
Figure 4. Antitumor activity of anti-FGFR1 mAb in combination with IFN-a in a murine xenograft tumor model of human HCC.
A, Representative photos of tumor grafts on SCID mice. B, In the graph, the sizes of the tumors in each group (n=4 mice per group) are shown on the
vertical axis, and the elapsed time after treatment with the indicated drugs and cells is shown on the horizontal axis. Symbols and bars are means 6
SD. C, Tumor volumes following treatment with the indicated drugs and cells. PBS is the negative control. Data are means 6 SD.
doi:10.1371/journal.pone.0019618.g004
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buffer, incubated for 1 h in 70% methanol at 4uC, and then washed
again. To examine expression of FGFR1, the fixed cells were
incubated first with anti-FGFR1 antibody (1:100 dilution) for 1 h at
4uC. The cells were then washed twice and incubated for 30 min in
4 mL of fluorescein isothiocyanate-conjugated goat anti-mouse IgG
on ice in the dark. After again washing the cells twice, they were
suspended in 1 mL of washing buffer for analysis using a FACScan
(Becton Dickinson Immunocytometry System, San Jose, CA, USA).
Analysis of FGFR1 expression in human hepatic cancer
xenografts
HepG2 cells (1610
6 cells) were xenografted into SCID mice.
When the resultant tumor reached 10 mm in diameter, IFN-a
(OIFH) or IFN-b (FeronH) was administered intraperitoneally or
intravenously at a dose of 100 U/g, and 24 h later tumor tissues
were collected. Western blot and immunohistochemical analyses
were then performed using an anti-human FGFR1 antibody
(sc-121; Santa Cruz Biotechnology).
Preparation of Anti-FGFR1 Antibody
A polynucleotide encoding the region extending from amino acid 1
to 822 of FGFR1 and represented by SEQ ID NO. 1 was amplified
by PCR using full-length FGFR1 (Accession No. NM_000604) as a
template with primers No. 59-3 [(SEQ ID NO. 3): 59-ACGGGATC-
CAGGACCCTGGCTGGAGAGACA-39]a n dN o .3 9-3 [(SEQ ID
NO. 4): 59-AAGCTCGAGCCGCCGGAACCGCGGCCGGA-
39]. The amplified polynucleotide was inserted into pcDNA3.1
Figure 5. Accumulation of anti-FGFR1 mAb in tumor xenografts is enhanced by IFN-a. A, SCID mice were xenografted with 1610
6 HepG2
cells, after which 50 mg of Cy5-conjugated A2C9-1 mAb was intravenously administrated via the tail vein. Mice were then imaged under anesthesia.
B, Time course of the Cy5 signal intensity.
doi:10.1371/journal.pone.0019618.g005
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vector that was administered as the immunizing antigen at a dose
of 50 mg/mouse in a 50-mL volume at 1- or 2-week intervals. The
antigen for the initial immunization was admixed with complete
Freund’s adjuvant, while the antigens for the second and
subsequent administrations were admixed with incomplete
Freund’s adjuvant. Spleen monocytic cells from the immunized
mouse and a fusion partner, X63-Ag8-653, were fused using
polyethylene glycol-mediated cell fusion, which was followed by
selection of a hybridoma using the method of Kinebuchi et al.
[28]. Cells that had reacted with the immobilized FGFR1 were
cultured in serum-free GIT medium (Wako Pure Chemical
Industries, Ltd., Osaka, Japan) to produce mAbs until 80% of the
cells had died. The cells were then removed from this medium by
centrifugation (1,000 rpm, 15 min), and ammonium sulfate was
added to 50% saturation and left overnight at 4uC. The resultant
precipitates were recovered by centrifugation (1,000 rpm,
30 min) and dissolved in two-fold diluted binding buffer (Protein
AMAPS II kit), after which the IgG was adsorbed onto a protein
A column (GE Healthcare Life Science). After eluting the mAbs
from the column, the eluate was dialyzed against PBS overnight
to purify the antibodies, which yielded a number of mAbs
recognizing FGFR1. One of those mAbs was designated A2C9-1
and was confirmed to recognize FGFR1 by Western blotting and
FACS using samples of FGFR1 expressed in NIH3T3 cells.
Affinity measurement
The affinity of anti-FGFR1 mAbs for FGFR1 was determined
based on surface plasmon resonance (SPR) using a Biacore 3000
device (Biacore AB, Uppsala, Sweden). The extracellular domain
of FGFR1 was covalently coupled to a CM-5 sensor chip at low
density (215 response units of FGFR1). Binding kinetics were then
assessed using twofold serial dilutions of antibody at concentrations
ranging from 500 to 0.08 nM in running buffer (PBS, pH 7.4,
0.005% (v/v), polysorbate 20 – filtered and degassed) at 25uC and
a flow rate of 25 ml/min. The regeneration procedure consisted of
three injections of 10 ml of 2.5 M guanidinium hydrochloride,
after which the sensor chip was flushed for 5 min with running
buffer. Statistics and data processing were performed using BIA
evaluation software 4.0.1 and GraphPad Prism 4.02 (GraphPad
Software Inc., San Diego, CA, USA). All SPR experiments were
carried out at Biaffin GmbH & Co. KG (Kassel, Germany).
Assessing the effect of anti-FGFR1 mAb on hepatic
cancer cell viability
To examine the effect of administering IFN-a (OIFH)i n
combination with anti-FGFR1 mAb (A2C9-1 or A2D11-1) to
HCC cells, we assessed the survival rate of HepG2 cells in the
presence and absence of IFN-a and/or anti-FGFR1 mAb. HepG2
cells were seeded into the wells of a 24-well plate to a density of
1610
4 cells/well, after which anti-FGFR1 mAb, IFN-a or anti-
FGFR1 mAb+IFN-a was added, and the culture was continued
for 0 to 6 days. The cells were then detached using trypsin, and the
survival rate was assessed using MTT assays. Antibody-free culture
medium was added as negative control, and cells to which nothing
was added were used as an additional control.
Therapeutic experiment with human hepatic cancer
cells-xenografted mouse
HepG2 cells (5610
6 cells/mouse) were xenografted subcutane-
ously into the backs of CB17-scid/scid mice. When the volumes of
the tumors reached 100 mm
3, the mice were divided into 7
treatment groups: 1) Mice in the PBS group received intravenous
injections of PBS (250 mL) and normal mouse IgG (100 mg). 2) The
IFN-a group received intraperitoneal injections of IFN-a (OIFH:
2000 U) and normal mouse IgG (100 mg). 3) The antibody group
received intravenous injections of PBS and anti-FGFR1 mAb
(100 mg; A2C9-1). 4) The IFN-a+antibody group received
intraperitoneal injections of IFN-a (2000 U) and intravenous
injections of anti-FGFR1 mAb (100 mg). 5) The IFN-a+antibo-
dy+PBMC group received intraperitoneal injections of IFN-a
(2000 U), intravenous injections of anti-FGFR1 mAb (100 mg) and
intravenous administration of PBMCs (1610
7 cells). 6) The IFN-
a+PBMC group received intraperitoneal injections of IFN-a
(2000 U) and intravenous administration of PBMCs (1610
7 cells).
7) The PBMC group received intravenous administration of
PBMCs (1610
7 cells). Treatments were administered 5 times in
total, beginning on day 0 and then 1 week later (w1), 2 weeks later
(w2), 5 weeks later (w5) and 6 weeks later (w6). Only at w6, the
antibody dose was increased to 200 mg/mouse. Each group
contained 4 animals, and the size of tumor was measured as
(major axis)6(minor axis)62 weekly after initial administration.
Tumors were harvested 1 week after the final treatment.
Immunophotodetection in tumor-bearing mice
HepG2 human HCC cells (1610
6 cells) were xenografted into
the backs of SCID mice. Three weeks later, when the inoculated
tumor had reached about 10 mm in diameter, IFN-a (OIF;
Otsuka Pharmaceutical Co., Ltd.) at a dose of 20,000 U/mouse or
PBS (control) was intraperitoneally administered. After 24 h,
50 mg of Alexa Fluor 680-conjugated anti-FGFR1 mAb was
intravenously administrated via the tail vein. The mice were then
imaged under anesthesia using an IVIS LUMINA imaging system
(Caliper Life Sciences, Hopkinton, MA, USA).
Supporting Information
Figure S1 Induction of FGFR1 transcripts by IFN-a and
IFN-b. HepG2 cells (1610
6 cells) were subcutaneously xenograft-
ed into the backs of SCID mice. When the inoculated tumor had
reached 10 mm in diameter, IFN-a or IFN-b was administered
intraperitoneally or intravenously at a dose of 2000 U/mouse.
Tumor tissues were then collected 0, 1, 3, 8, 24 and 48 h after
administration. A, Time-course of FGFR1 and OAS1 (control)
mRNA expression following administration of IFN-a. FGFR1
mRNA (blue line) was increased 3 h (151%), 8 h (202%) and 24 h
(119%) after administration. OAS1 mRNA (red line) was increased
3 h (162%), 8 h (133%) and 24 h (150%) after administration.
Shown are means of two replicates of the real-time RT-PCR. B,
Time-course of FGFR1 and OAS1 mRNA expression after
administration of IFN-b. FGFR1 mRNA (blue line) was increased
8 h (348%) and 24 h (337%) after administration, while OAS1
mRNA (red line) was increased 3 h (262%) and 8 h (511%) after
administration. The levels of mRNA expression were normalized
to that of GAPDH mRNA. The expression level at 0 h was taken
as 100%.
(TIFF)
Figure S2 Evaluation of anti-FGFR1 monoclonal anti-
bodies. A, Western blot analysis for FGFR1 in NIH3T3 cells
stably transfected for FGFR1. The antibodies used are shown
below the panel. B, Surface plasmon resonance analysis. The
affinity of anti-FGFR1 mAb for FGFR1 was determined based on
surface plasmon resonance. The extracellular domain of FGFR1,
which was fused to the constant region of mouse IgG1, was
covalently coupled to a CM-5 sensor chip at a density of 3400
response units. Binding kinetics were determined using two-fold
serial dilutions of antibody at concentrations ranging from 200 to
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PLoS ONE | www.plosone.org 8 May 2011 | Volume 6 | Issue 5 | e1961812.5 nM in running buffer (PBS, pH 7.4, filtered and degassed).
The regeneration procedure was carried using 15 mLo f3 M
sodium thiocyanate. B, The apparent association and dissociation
rate constants (ka1 (1/Ms) and kd1 (1/s)) and Kd values for A2C9-
1 and A2D11-1.
(TIFF)
Figure S3 Histological analysis of human hepatic can-
cer cell-xenograft tumors. Hematoxylin and eosin (HE)
staining of xenograft tumors from mice treated with PBMC only,
IFN-a only, A2C9-1 only, IFN-a+A2C9-1 and IFN-a+A2C9-
1+PBMC. Tumors were harvested 1 week after the final
treatment. Note the marked infiltration by mononuclear lympho-
cytes of tumors from mice treated with IFN-a+A2C9-1+PBMC
and the absence of infiltration of tumors from the other groups.
(TIFF)
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